



Implementation of the Mandatory Squeeze-out for the Shares of QIAGEN Marseille

This press release was prepared by QIAGEN N.V. and circulated in accordance with Article 237-16 III of the AMF General Regulations and the AMF's Instruction number 2006-07 relating to tender offers.

Marseille, 26 June 2015

In accordance with Articles 237-14 et seq of the AMF General Regulations, QIAGEN N.V., a company incorporated under the laws of the Netherlands, whose registered office is located at Spoorstraat 50, 5911 KJ Venlo, Netherlands, and registered under number 12036979 ("**QIAGEN**" or the "**Offeror**") applied to the French Financial Markets Authority (*Autorité des Marchés Financiers*) (the "**AMF**") for the implementation of the mandatory squeeze-out process for the shares of QIAGEN Marseille ("**QIAGEN Marseille**" or the "**Company**"), a French public limited-liability company with a board of directors (*société anonyme à conseil d'administration*), with a share capital of EUR 1,089,116.60, whose registered office is located at Luminy Biotech Enterprise Case 923 13288, 163 avenue de Luminy, Marseille Cedex 09, France, registered with the Commercial and companies registrar of Marseille under number 424 364 412, and whose shares are traded on the Alternext Paris under ISIN Code FR0010626028.

The implementation of the mandatory squeeze-out process was approved by the AMF on 25 June 2015 in decision number D&I215C0900.

As of the date hereof, QIAGEN holds 5,345,614 shares of QIAGEN Marseille, including Assimilated Shares¹, representing 98.16% of the Company's share capital, and 10,303,106 voting rights representing 98.80% of the Company's voting rights².

Terms and Conditions of the Mandatory Squeeze-out

The mandatory squeeze-out will cover all of the shares of QIAGEN Marseille, except the shares of QIAGEN Marseille held by the Offeror and the Assimilated Shares, i.e. 99,969 shares representing 125,247 voting rights (i.e. 1.84% of the share capital and 1.20% of the voting rights).

The shares of QIAGEN Marseille covered by the mandatory squeeze-out will be transferred to the Offeror in return for the payment of a price identical to the price of the Offer, EUR 14.90 net of all costs, to their holder.

¹ Between 5 May and 4 June 2015, QIAGEN concluded Liquidity Commitments regarding a total number of 154,657 shares of QIAGEN Marseille representing 254,240 voting rights (the "**Assimilated Shares**").

² Taking into consideration a total number of 5,445,583 shares and a total number of 10,433,353 voting rights as of 17 June 2015, based on the shareholders register as of that date.

In accordance with Article 237-4 of the AMF General Regulations, Kepler Capital Markets will centralize the payment operations.

The funds that will not have been allocated to the payment operations will be kept by Kepler Capital Markets for ten years and then transferred to the Caisse des dépôts et consignation.

The mandatory squeeze-out will be effective as of 29 June 2015 and the shares of QIAGEN Marseille will be delisted from Alternext Paris on that date.

All public documentation relating to the Offer is available on the websites of the AMF (www.amf-france.org) and of the Company (www.qiagenmarseille.com), namely:

- QIAGEN N.V.'s information memorandum approved by the AMF on 14 April 2015 under number 15-151;
- QIAGEN Marseille's information memorandum in response approved by the AMF on 14 April 2015 under number 15-152;
- QIAGEN N.V.'s other information document filed with the AMF on 14 April 2015;
- QIAGEN Marseille's other information document filed with the AMF on 14 April 2015.

Contacts:

QIAGEN N.V.

Public Relations:

Dr. Thomas Theuringer
Director Public Relations
+49 2103 29 11826
+1 240 686 7425

Email: pr@qiagen.com

www.twitter.com/qiagen
pr.qiagen.com

Press relations

Marie Puvieux, ATCG Press

Tel: + 33 (0)6 10 54 36 72

presse@atcg-partners.com



Investor Relations:

John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222

Email: ir@qiagen.com